Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis


Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge

Telaprevir /Peginterferon/ribavirin (RBV) algorithm

for Health Care Providers

Therapy against Hepatitis C in Patients with Genotype 1 Infection

Back to Appendix

Figure 2. Telaprevir (TVR)/Peginterferon (PegIFN)/ribavirin (RBV)* algorithm for both treatment-naive and treatment-experienced patients with HCV genotype 1

Figure 2

* PegIFN alfa-2a 180 mcg per week or PegIFN alfa-2b 1.5 mcg/kg per week. RBV (in two divided doses) with food: <75 kg: 1,000 mg per day or ≥ 75 kg: 1,200 mg per day; alternative weight-based RBV dosing: <65 kg: 800 mg per day, 65-85 kg: 1,000 mg per day, >85-105 kg: 1,200 mg per day, >105 kg: 1,400 mg per day. TVR 750 mg (two 375 mg tablets) orally every 8 h with food (20 g fat).

† A sensitive real-time quantitative HCV RNA assay with a lower limit of detection of <10-15 IU/ml should be used for decision-making to determine treatment duration with response-guided therapy (RGT).